Enhancing Therapeutic Response in Gastroesophageal Reflux Disease: The Role of Mirgeal® gel

Over 40% of patients suffering from Gastroesophageal Reflux Disease still grapple with symptoms despite relying on proton pump inhibitors (PPIs). A dedicated review explores advanced therapies to support them, unveiling Mirgeal® gel as a revolutionary adjunctive treatment.

With unique ingredients like licorice extract and Mirtoselect®, Mirgeal® gel outperforms traditional options, providing lasting relief and transforming GERD care.

Unmet challenges in GERD treatment: bridging the gap with adjunctive therapies

More than 40% of patients suffering from Gastroesophageal Reflux Disease (GERD) persistently grapple with symptoms, despite relying on proton pump inhibitors (PPIs). This scenario highlights the significant need for advanced therapies to elevate treatment responses and alleviate patient discomfort.

In a review titled “A Review of Medical Therapy for Proton Pump Inhibitor Nonresponsive Gastroesophageal Reflux Disease”, published in a journal specialized in esophageal diseases, researchers meticulously analyzed clinical studies exploring adjunctive therapies alongside PPIs. From an exhaustive pool of nearly 3000 clinical trials, only 40 studies were deemed of satisfying quality for inclusion in this comprehensive analysis.

The review illuminated that differences between PPI responders and non-responders may have a genetic basis, specifically linked to the CYP2C19 polymorphism. This insight suggests the potential benefits of tailoring PPI prescriptions to individual molecular profiles, explaining why certain patients derive greater benefits from specific PPI molecules within the same pharmacological class.

Whatever it may be, both responders and non-responders to PPIs stand to gain from additional therapeutic tools harnessing diverse mechanisms of action. The selected studies explored molecules such as histamine receptor antagonists, specific prokinetics, and formulations with mucoprotective properties. Notably, Mirgeal® gel emerged as the sole nutritional supplement with a study featured in this comprehensive Review of Adjunctive Therapies for reflux disease. Mirgeal® gel is a unique product composed of alginate potentiated by the presence of two botanical extracts that exert protective properties on the gastroesophageal mucosa.

Mirgeal®: The important results obtained versus alginate

The study conducted on Mirgeal®, in patients with reflux disease, showcased how an adjunctive therapy with distinctive characteristics can markedly enhance outcomes. In this compelling study, the intervention group seamlessly combined PPIs with Mirgeal® (2 stick packs/day) for four weeks, followed by a further four weeks of Mirgeal® alone. This group was compared to another receiving PPIs combined with alginate following the same dosage and regimen (for a complete explanation of the study, you can read the previous article on Mirgeal® gel).

After two months, both treatments effectively mitigated symptoms. However, the Mirgeal® gel group exhibited significantly greater improvement from the 2nd week onwards, persisting until the study’s conclusion. Results conclusively demonstrated that Mirgeal® gel outperformed alginate alone, both in combination with PPIs and as a monotherapy, maintaining improvements even after drug discontinuation.

Mirgeal® gel’s superior efficacy is attributed to its unique formulation, featuring:

  • licorice extract known for its anti-inflammatory and anti-ulcer properties.
  • Mirtoselect®, a special blueberry extract offering cytoprotective action.

These extracts, enveloped in an alginate matrix that ensures prolonged contact with the gastric mucosa, extending the duration of their beneficial action.

Mirgeal® gel is poised to revolutionize reflux disease treatment, offering an advanced approach that transcends traditional therapies. With its innovative formulation and documented effectiveness, Mirgeal® gel emerges as a promising solution for those seeking a new tool providing lasting relief from the burdens of gastroesophageal reflux disease.